-
EP4013496
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4013496
| EP4013496 - THROMBOSOMES AS AN ANTIPLATELET AGENT REVERSAL AGENT [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 20.05.2022 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 26.02.2021 | Most recent event Tooltip | 27.08.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Cellphire Inc. 9430 Key West Avenue Rockville, MD 20850 / US | [2022/25] | Inventor(s) | 01 /
MOSKOWITZ, Keith Andrew 14974 Dawnhaven Drive Westfield, Indiana 46074 / US | 02 /
ISHLER, Braden Carl 410 Blue Silk Lane, Apt H Gaithersburg, Maryland 20879 / US | 03 /
DICKERSON, William Matthew 1401 Church St. NW 311 Washington, District of Columbia 20005 / US | 04 /
TANDON, Narendra Nath 7102 Strators Lane Gaithersburg, Maryland 20189 / US | 05 /
LEE, Amber Nicole 1747 Yale Pl. Rockville, Maryland 20850 / US | [2022/25] | Representative(s) | Turner, Craig Robert, et al AA Thornton IP LLP 8th Floor, 125 Old Broad Street London EC2N 1AR / GB | [N/P] |
| Former [2022/25] | Fish & Richardson P.C. Highlight Business Towers Mies-van-der-Rohe-Straße 8 80807 München / DE | Application number, filing date | 20855485.7 | 14.08.2020 | [2022/25] | WO2020US46525 | Priority number, date | US201962887923P | 16.08.2019 Original published format: US 201962887923 P | US202063065337P | 13.08.2020 Original published format: US 202063065337 P | [2022/25] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021034719 | Date: | 25.02.2021 | Language: | EN | [2021/08] | Type: | A1 Application with search report | No.: | EP4013496 | Date: | 22.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.02.2021 takes the place of the publication of the European patent application. | [2022/25] | Search report(s) | International search report - published on: | US | 25.02.2021 | (Supplementary) European search report - dispatched on: | EP | 15.09.2023 | Classification | IPC: | A61K31/197, A61K35/19, A61P7/04, A61K31/137, A61K31/195, A61K38/16, A61K38/55, A61K31/7016, A61K31/192, A61K31/245, A61K9/00, A61K31/4365, A61K31/4465, A61K45/06, A61K47/02, A61K47/26, A61K31/519, A61K31/616, A61K31/7076, A61K38/57 | [2023/42] | CPC: |
A61P7/04 (EP,IL,KR,US);
A61K35/19 (EP,IL,KR,US);
A61K31/192 (EP,IL);
A61K31/195 (EP);
A61K31/197 (EP);
A61K31/245 (EP);
A61K31/4365 (EP,IL);
A61K31/4465 (EP,IL);
A61K31/519 (EP,IL);
A61K31/616 (EP,IL);
A61K31/7016 (EP);
A61K31/7076 (EP,IL);
A61K38/363 (EP,IL);
A61K38/57 (EP,IL);
A61K45/06 (EP,IL,KR,US);
A61K47/02 (EP,IL);
A61K47/26 (EP,IL,KR,US);
A61K47/42 (IL,US);
| C-Set: |
A61K31/192, A61K2300/00 (EP);
A61K31/195, A61K2300/00 (EP);
A61K31/197, A61K2300/00 (EP);
A61K31/245, A61K2300/00 (EP);
A61K31/4365, A61K2300/00 (EP);
A61K31/4465, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K31/616, A61K2300/00 (EP);
A61K31/7016, A61K2300/00 (EP);
A61K31/7076, A61K2300/00 (EP);
A61K35/19, A61K2300/00 (EP);
A61K38/363, A61K2300/00 (EP); |
| Former IPC [2022/25] | A61P7/02, A61P7/04, A01N1/02 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/25] | Title | German: | THROMBOSOMEN ALS MITTEL ZUR AUFHEBUNG DER THROMBOZYTENAGGREGATIONSHEMMENDEN WIRKUNG | [2022/25] | English: | THROMBOSOMES AS AN ANTIPLATELET AGENT REVERSAL AGENT | [2022/25] | French: | THROMBOSOMES EN TANT QU'AGENT DÉSACTIVATEUR D'ANTIAGRÉGANT PLAQUETTAIRE | [2022/25] | Entry into regional phase | 11.03.2022 | National basic fee paid | 11.03.2022 | Search fee paid | 11.03.2022 | Designation fee(s) paid | 11.03.2022 | Examination fee paid | Examination procedure | 11.03.2022 | Examination requested [2022/25] | 25.03.2024 | Amendment by applicant (claims and/or description) | 25.03.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 11.03.2022 | Renewal fee patent year 03 | 28.08.2023 | Renewal fee patent year 04 | 27.08.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]EP0967862 (ELAN DRUG DELIVERY LTD [GB]); | [Y]WO2006020773 (ADLYFE INC [US], et al); | [Y]US2006051731 (HO DAVID [US], et al); | [IY]US8486617 (HO DAVID [US], et al) | International search | [Y]US2005181978 (ROJKJAER RASMUS [DK], et al); | [XY]WO2017040238 (CELLPHIRE INC [US]) |